Dr. Marcel van Den Brink is a medical oncologist and the head of the Memorial Sloan Kettering Cancer Center's Division of Hematologic Malignancies. He is currently the study chair of the clinical trial “ILIAD-7-US-O-InterLeukin-7 to improve Clinical Outcomes in Lymphopenic Patients with COVID-19 Infection” (NCT04426201).
Cancer patients with COVID-19, which has been associated with the depletion of important immune cells, are more vulnerable to severe disease and death due to their often compromised immune function. Compared to the general population, where 1-4% of patients die from COVID-19, between 13-28% of cancer patients succumb to the disease.
In this trial, treatment with recombinant human interleukin-7 (CYT107)—a cytokine which has been used to increase the levels of T cells in a variety of other diseases—will be investigated with respect to its ability to boost T cells in cancer patients with COVID-19. This trial will be one of the first seeking to understand how treatment with an immune-mediated cytokine might influence immune activity in the context of COVID-19 and cancer. Consequently, it could lead to important insights both for treating both COVID-19 and cancer in general.
Additional investigators working on this trial include:
- Stephen M. Pastores, M.D. (Memorial Sloan Kettering Cancer Center)
- Joseph Nates, M.D. (MD Anderson Cancer Center)
Projects and Grants
ILIAD-7-US-O-InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients with COVID-19 Infection (NCT04426201)
Memorial Sloan Kettering Cancer Center | All Cancers | 2020
Let's spread the word about Immunotherapy! Click to share this page with your community.